FDM Group stock falls on subdued 2025 outlook By Investing.com
Financial Performance: FDM Group's shares fell 8% after reporting a slight revenue increase but a 23% decline in organic growth and fewer completed trainings than expected, leading to a lower forecast for operating profit in 2025.
Market Reaction: Barclays has reduced its price target for FDM Group from 485p to 400p, citing challenges in the first half of the year while noting that conditions have stabilized.
Trade with 70% Backtested Accuracy
Analyst Views on FDM

No data
About the author


Overview of First Trust Dow Jones Select MicroCap ETF (FDM)
- Launch and Management: The First Trust Dow Jones Select MicroCap ETF (FDM) was launched on September 27, 2005, and is managed by First Trust Advisors.
- Assets Under Management: The ETF has accumulated over $200.34 million in assets, positioning it as an average-sized fund within the Small Cap Blend segment of the US equity market.
Investment Characteristics
- Market Capitalization Focus: FDM targets small cap companies with market capitalizations below $2 billion, which are generally considered high-potential but come with increased risk compared to larger companies.
- Blend Strategy: The ETF holds a mix of growth and value stocks, reflecting characteristics of both investment styles.
Cost and Performance Metrics
- Expense Ratio: The annual operating expenses for FDM are 0.6%, aligning it with most of its peers in the ETF space.
- Dividend Yield: It offers a 12-month trailing dividend yield of 1.32%.
- Performance: As of August 29, 2025, FDM has gained approximately 11.63% year-to-date and 20.19% over the past year, with a trading range between $55.48 and $75.59 in the last 52 weeks.
Portfolio Composition
- Sector Allocation: The ETF has a significant allocation to the Financials sector at 28.3%, followed by Industrials and Energy.
- Top Holdings: Centrus Energy Corp. (LEU) constitutes about 5.72% of total assets, with Turning Point Brands, Inc. (TPB) and Willdan Group, Inc. (WLDN) also among the top holdings. The top 10 holdings represent approximately 23.57% of total assets.
Risk and Ranking
- Risk Profile: FDM has a beta of 1.03 and a standard deviation of 21.81% over the trailing three-year period, categorizing it as a medium-risk investment.
- Zacks ETF Rank: The ETF holds a Zacks ETF Rank of 3 (Hold), indicating a moderate outlook based on expected returns, expense ratios, and momentum.
Comparison with Other ETFs
- Similar ETFs: The iShares Russell 2000 ETF (IWM) and iShares Core S&P Small-Cap ETF (IJR) are comparable options, with IWM managing $67.45 billion and IJR $85.42 billion. IWM has an expense ratio of 0.19%, while IJR charges 0.06%.
Conclusion
- Investment Appeal: FDM is a viable option for investors seeking exposure to the Small Cap Blend market, offering low costs, transparency, and diversification. It is particularly appealing for long-term investors and is popular among both institutional and retail investors.
Financial Performance: FDM Group's shares fell 8% after reporting a slight revenue increase but a 23% decline in organic growth and fewer completed trainings than expected, leading to a lower forecast for operating profit in 2025.
Market Reaction: Barclays has reduced its price target for FDM Group from 485p to 400p, citing challenges in the first half of the year while noting that conditions have stabilized.
Mpox Outbreak and Global Response: Authorities in Europe and China are increasing screening for a new strain of mpox, known as clade I, which has been confirmed in Sweden and is spreading in Africa. The World Health Organization has declared it a global health emergency, with over 16,000 cases reported in Africa this year.
Vaccination Efforts and Treatment Challenges: Two vaccines have received emergency authorizations, with efforts to expand their use among at-risk populations. However, a study indicated that the antiviral drug tecovirimat did not reduce the duration of mpox lesions in affected individuals.
Clearwater Paper Corporation's Sale: Clearwater Paper Corporation is selling its tissue business to Sofidel America Corporation for $1.06 billion, marking a significant step in its transformation into a leading paperboard supplier in North America.
Financial Impact and Future Plans: The sale is expected to yield approximately $850 million in net proceeds, which will be used to reduce debt and support growth initiatives, as the company aims to enhance its paperboard operations.

- Avian Influenza Spread: Bird flu, particularly the H5N1 strain, has spread to an unprecedented number of cows in the U.S. this year, with four dairy workers testing positive for the virus.
- Global Impact: Severe variants of the H5N1 strain have infected various animals worldwide since 2020, causing lethal outbreaks in commercial poultry and now infecting cows for the first time.
- Human Cases: Humans have contracted different bird flu strains in Australia and Mexico, with concerns about potential mutations that could facilitate human-to-human transmission.
- Preventive Measures: The World Health Organization states the current risk to people is low, but there are efforts to prevent further spread, such as tracking farm visitors and testing individuals in affected states.
- Market Response: Companies developing bird flu vaccines saw stock gains, while dairy and agriculture-related stocks had mixed reactions. Additionally, an investor backing Moderna raised $3.6 billion for AI-driven biotech ventures.
- ETF Analyst Target Price Comparison: ETF Channel compared trading prices of holdings against average analyst 12-month forward target prices to find implied analyst target price for First Trust Dow Jones Select MicroCap Index Fund ETF (FDM) at $74.03 per unit.
- Upside Potential: Analysts see 24.58% upside for FDM ETF based on average analyst targets of underlying holdings like RCMT, TZOO, and LSEA.
- Notable Upside Stocks: RCMT has 86.92% upside, TZOO has 68.92% upside, and LSEA has 66.09% upside according to average analyst target prices.
- Analyst Target Price Table: A summary table of current analyst target prices for the mentioned stocks is provided.
- Investor Considerations: Questions raised about analysts' justification for targets, optimism, and need for further investor research.









